A novel angiotensin I-converting enzyme inhibitory peptide derived from the trypsin hydrolysates of salmon bone proteins.

When fish are processed, fish bone becomes a key component of the waste, but to date very few researchers have sought to use fish bone to prepare protein hydrolysates as a means of adding value to the final product. This study, therefore, examines the potential of salmon bone, through an analysis of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thanakrit Kaewsahnguan, Sajee Noitang, Papassara Sangtanoo, Piroonporn Srimongkol, Tanatorn Saisavoey, Onrapak Reamtong, Kiattawee Choowongkomon, Aphichart Karnchanatat
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/48c996bb5cb64400b635ac146281850f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:48c996bb5cb64400b635ac146281850f
record_format	dspace
spelling	oai:doaj.org-article:48c996bb5cb64400b635ac146281850f2021-12-02T20:08:37ZA novel angiotensin I-converting enzyme inhibitory peptide derived from the trypsin hydrolysates of salmon bone proteins.1932-620310.1371/journal.pone.0256595https://doaj.org/article/48c996bb5cb64400b635ac146281850f2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0256595https://doaj.org/toc/1932-6203When fish are processed, fish bone becomes a key component of the waste, but to date very few researchers have sought to use fish bone to prepare protein hydrolysates as a means of adding value to the final product. This study, therefore, examines the potential of salmon bone, through an analysis of the benefits of its constituent components, namely fat, moisture, protein, and ash. In particular, the study seeks to optimize the process of enzymatic hydrolysis of salmon bone with trypsin in order to produce angiotensin-I converting enzyme (ACE) inhibitory peptides making use of response surface methodology in combination with central composite design (CCD). Optimum hydrolysis conditions concerning DH (degree of hydrolysis) and ACE-inhibitory activity were initially determined using the response surface model. Having thus determined which of the salmon bone protein hydrolysates (SBPH) offered the greatest level of ACE-inhibitory activity, these SBPH were duly selected to undergo ultrafiltration for further fractionation. It was found that the greatest ACE-inhibitory activity was achieved by the SBPH fraction which had a molecular weight lower than 0.65 kDa. This fraction underwent further purification using RP-HPLC, revealing that the F7 fraction offered the best ACE-inhibitory activity. For ACE inhibition, the ideal peptide in the context of the F7 fraction comprised eight amino acids: Phe-Cys-Leu-Tyr-Glu-Leu-Ala-Arg (FCLYELAR), while analysis of the Lineweaver-Burk plot revealed that the FCLYELAR peptide can serve as an uncompetitive ACE inhibitor. An examination of the molecular docking process showed that the FCLYELAR peptide was primarily able to provide ACE-inhibitory qualities as a consequence of the hydrogen bond interactions taking place between ACE and the peptide. Furthermore, upon isolation form the SBPH, the ACE-inhibitory peptide demonstrated ACE-inhibitory capabilities in vitro, underlining its potential for applications in the food and pharmaceutical sectors.Thanakrit KaewsahnguanSajee NoitangPapassara SangtanooPiroonporn SrimongkolTanatorn SaisavoeyOnrapak ReamtongKiattawee ChoowongkomonAphichart KarnchanatatPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0256595 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Thanakrit Kaewsahnguan Sajee Noitang Papassara Sangtanoo Piroonporn Srimongkol Tanatorn Saisavoey Onrapak Reamtong Kiattawee Choowongkomon Aphichart Karnchanatat A novel angiotensin I-converting enzyme inhibitory peptide derived from the trypsin hydrolysates of salmon bone proteins.
description	When fish are processed, fish bone becomes a key component of the waste, but to date very few researchers have sought to use fish bone to prepare protein hydrolysates as a means of adding value to the final product. This study, therefore, examines the potential of salmon bone, through an analysis of the benefits of its constituent components, namely fat, moisture, protein, and ash. In particular, the study seeks to optimize the process of enzymatic hydrolysis of salmon bone with trypsin in order to produce angiotensin-I converting enzyme (ACE) inhibitory peptides making use of response surface methodology in combination with central composite design (CCD). Optimum hydrolysis conditions concerning DH (degree of hydrolysis) and ACE-inhibitory activity were initially determined using the response surface model. Having thus determined which of the salmon bone protein hydrolysates (SBPH) offered the greatest level of ACE-inhibitory activity, these SBPH were duly selected to undergo ultrafiltration for further fractionation. It was found that the greatest ACE-inhibitory activity was achieved by the SBPH fraction which had a molecular weight lower than 0.65 kDa. This fraction underwent further purification using RP-HPLC, revealing that the F7 fraction offered the best ACE-inhibitory activity. For ACE inhibition, the ideal peptide in the context of the F7 fraction comprised eight amino acids: Phe-Cys-Leu-Tyr-Glu-Leu-Ala-Arg (FCLYELAR), while analysis of the Lineweaver-Burk plot revealed that the FCLYELAR peptide can serve as an uncompetitive ACE inhibitor. An examination of the molecular docking process showed that the FCLYELAR peptide was primarily able to provide ACE-inhibitory qualities as a consequence of the hydrogen bond interactions taking place between ACE and the peptide. Furthermore, upon isolation form the SBPH, the ACE-inhibitory peptide demonstrated ACE-inhibitory capabilities in vitro, underlining its potential for applications in the food and pharmaceutical sectors.
format	article
author	Thanakrit Kaewsahnguan Sajee Noitang Papassara Sangtanoo Piroonporn Srimongkol Tanatorn Saisavoey Onrapak Reamtong Kiattawee Choowongkomon Aphichart Karnchanatat
author_facet	Thanakrit Kaewsahnguan Sajee Noitang Papassara Sangtanoo Piroonporn Srimongkol Tanatorn Saisavoey Onrapak Reamtong Kiattawee Choowongkomon Aphichart Karnchanatat
author_sort	Thanakrit Kaewsahnguan
title	A novel angiotensin I-converting enzyme inhibitory peptide derived from the trypsin hydrolysates of salmon bone proteins.
title_short	A novel angiotensin I-converting enzyme inhibitory peptide derived from the trypsin hydrolysates of salmon bone proteins.
title_full	A novel angiotensin I-converting enzyme inhibitory peptide derived from the trypsin hydrolysates of salmon bone proteins.
title_fullStr	A novel angiotensin I-converting enzyme inhibitory peptide derived from the trypsin hydrolysates of salmon bone proteins.
title_full_unstemmed	A novel angiotensin I-converting enzyme inhibitory peptide derived from the trypsin hydrolysates of salmon bone proteins.
title_sort	novel angiotensin i-converting enzyme inhibitory peptide derived from the trypsin hydrolysates of salmon bone proteins.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/48c996bb5cb64400b635ac146281850f
work_keys_str_mv	AT thanakritkaewsahnguan anovelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT sajeenoitang anovelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT papassarasangtanoo anovelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT piroonpornsrimongkol anovelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT tanatornsaisavoey anovelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT onrapakreamtong anovelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT kiattaweechoowongkomon anovelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT aphichartkarnchanatat anovelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT thanakritkaewsahnguan novelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT sajeenoitang novelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT papassarasangtanoo novelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT piroonpornsrimongkol novelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT tanatornsaisavoey novelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT onrapakreamtong novelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT kiattaweechoowongkomon novelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins AT aphichartkarnchanatat novelangiotensiniconvertingenzymeinhibitorypeptidederivedfromthetrypsinhydrolysatesofsalmonboneproteins
_version_	1718375177585164288

A novel angiotensin I-converting enzyme inhibitory peptide derived from the trypsin hydrolysates of salmon bone proteins.

Ejemplares similares